Barinthus Biotherapeutics logo
Barinthus Biotherapeutics
BRNS | NASDAQ
Chart Builder DCF Calculator
$0.74
-$0.02 (-2.50%)
At close: Sep 8, 2026, 4:00 PM ET

Barinthus Biotherapeutics Company Profile

Company profile explained

Company Profile

Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for treating autoimmune and inflammatory diseases. The company is prioritizing the development of its proprietary SNAP-TI platform, designed to promote immune tolerance, with its lead candidate VTP-1000 targeting celiac disease. It is also developing VTP-300 for chronic hepatitis B using viral vector platform technologies, aimed at inducing disease-specific immune responses.

Key Executives

Name Position
William J. Enright Chief Executive Officer & Director
Douglas J. Swirsky CFO & Principal Accounting Officer
Leon Hooftman Chief Medical Officer

Latest SEC Filings

Date Type Title
Sep 21, 2026 15-12G Filing
Sep 14, 2026 EFFECT Filing
Sep 11, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Sep 11, 2026 4/A [Amend] Filing
Sep 09, 2026 25 Filing
Sep 09, 2026 4 Filing
Sep 09, 2026 4 Filing
Sep 09, 2026 4 Filing
Sep 09, 2026 4 Filing
Sep 09, 2026 4 Filing
View All SEC Filings ➞
Barinthus Biotherapeutics
Barinthus Biotherapeutics logo
Country United States
IPO Date Apr 30, 2021
Industry Biotechnology
Sector Healthcare
Employees 14
CEO William James Enright

Contact Details

20400 Century Boulevard Germantown, Maryland 20874 United States

Stock Details

Ticker Symbol BRNS
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001828185
CUSIP Number 91864C107
ISIN Number US91864C1071
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.